FDA对印度班加罗尔原料药厂发出警告信,指约1,500起OOS实验室事件调查不足
FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
FDA对印度班加罗尔原料药企业Cdymax India Pharma Private Limited发出2025年11月13日警告信,指自2023年以来约1,500起OOS及重大分析事件的实验室调查与CAPA存在系统性缺陷。
材料以具体缺陷案例呈现FDA对OOS调查充分性与CAPA有效性的核查关注点,可供实验室调查审阅对照。
The U.S. Food and Drug Administration has issued a Warning Letter dated 13 November 2025 following an inspection of an API manufacturing site in Bangalore (India) conducted in April 2025. The authority identified systemic failures in the handling of Out-of-Specification (OOS) results, laboratory investigations, and the overall CAPA system. 1,500 Laboratory Incidents Involving OOS Results The FDA states that since 2023, approximately 1,500 laboratory incidents (including OOS results and major analytical events) were recorded. The FDA found that: OOS investigations were frequently scientifically inadequate, root cause analyses were missing or superficial, CAPAs were ineffective or inconsistent, and manufacturing investigations were often not initiated, despite inconclusive laboratory root causes. Critical Example Cited by FDAAs only one example out of numerous inadequate investigations observed during the inspection, the authority describes the following case: Repeated OOS results due to an “unknown peak” in stability samples were invalidated after a later passing re-test using freshly prepared solutions. The FDA criticized that: the contaminant was never identified, the origin and cause remained unclear, no manufacturing investigation was conducted, and the implemented CAPA (“refresher training”) was not scientifically justified. In this context, the FDA mentions that the "corrective action of providing 'refresher training for personnel on good laboratory practice' contradicted the investigation’s own initial finding that the analyst was trained and qualified to perform the HPLC test according to your procedure." Regulatory Expectation Emphasized by FDA The FDA points out that a suspected laboratory error alone is insufficient to close an OOS investigation. If no conclusive laboratory root cause is demonstrated, a full manufacturing investigation is mandatory. The FDA requests, among other things: independent system-wide reassessment of the OOS and deviation investigation system, retrospective review of all OOS cases over the last four years, including already released U.S. batches. Additional Laboratory-Related DeficiencyThe FDA also identified major shortcomings in method validation and verification. Several in-house analytical methods were inadequately validated, with deficiencies in precision, robustness, and system suitability testing. For further information, please see the complete Warning Letter to Cdymax India Pharma Private Limited on the FDA's website.
来源:ECA GMP News · gmp-compliance.org